|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used computational target gene prediction, <i>in vitro</i> cell culture, immunoblotting, quantitative real-time PCR, ATP measurements, luciferase reporter assays, wound-healing assays, Transwell assays, RNA immunoprecipitation PCR, co-immunoprecipitation, flow cytometry and tumor xenografts to study the regulation of the PKM2/β-catenin axis in glioma.
|
28858851 |
2017 |
|
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokines related to glioma risk (P ≤ .05) more than 10 years before diagnosis are sIL10RB, VEGF, beta-Catenin and CCL22.
|
28594935 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study validates a pathogenetic role of miR-19 in glioma and establishes a potentially regulatory and signaling involving miR-19 /RUNX3/β-catenin, also suggesting miR-19 may be a candidate therapeutic target in glioma.
|
29340016 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, β-catenin partially mediated the effect of YAP on glioma cell proliferation.
|
28962630 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrates that the inhibition of β-catenin in CSCs by Tet could be an effective strategy for the treatment of glioma.
|
27909720 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with demethylating agent (5-aza-2'-deoxycytidine) or exogenous expression of Six3 restored Six3 production and resulted in suppression of cell cycle G1/S transition, proliferation and invasion and down-regulation of the expression of Wnt1, p-GSK3-β, β-catenin and cyclin D1 in glioma U251 cells.
|
28643150 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, we aimed to investigate NCTD as an anti-neoplastic drug that inhibits the Wnt/β‑catenin pathway via promoter demethylation of Wnt inhibitory factor-1 (WIF-1) in glioma growth in vitro.
|
26781164 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As we demonstrated earlier that α5β1 integrin may be considered as a therapeutic target in high grade glioma through its contribution to glioma cell migration and resistance to chemotherapy, we addressed here the potential relationship between α5β1 integrin and beta-catenin activation in glioma cells.
|
27613837 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway.
|
27166258 |
2016 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of WNT3a, cytoplasmic β-catenin and TCF4 was significantly associated with the histological malignancy grade and with a worse prognosis for patients with glioma.
|
26708597 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TIPE2 Inhibits Hypoxia-Induced Wnt/β-Catenin Pathway Activation and EMT in Glioma Cells.
|
27656836 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of USP9X also consistently inhibits the tumorigenicity of primary glioma cells in vivo.In summary, these results indicate that USP9X stabilizes β-catenin and activates Wnt/β-catenin signal pathway to promote glioma cell proliferation and survival.
|
27783990 |
2016 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Kindlin-2 interacts with β-catenin and YB-1 to enhance EGFR transcription during glioma progression.
|
27713156 |
2016 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that KLF8 modulates glioma cell resistance to TMZ via activation of β-catenin; therefore, therapies that inhibit KLF8 levels in glioma can enhance the efficacy of TMZ treatment.
|
27081861 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests that SPOCK1 promotes proliferation, migration and invasion in glioma cells by activating PI3K/AKT and Wnt/β-catenin pathways, which provides a potential theoretical basis for clinical treatment of glioma.
|
27108836 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
|
27006177 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although aberrant nuclear accumulation of β-catenin is linked to the malignant progression of gliomas, its association with IDH1 remains unknown.
|
26860959 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to characterize the mechanism behind cross-talk between GRβ and β-catenin/TCF in the progression of glioma.
|
25301232 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we studied phosphoY142 (PY142) β-catenin and dephospho S/T β-catenin (a classical Wnt transducer) in glioma biopsies, GBM cell lines and biopsy-derived glioma cell cultures.
|
26654598 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1.
|
25681036 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate a novel Wnt/β-catenin-miR-30a-5p-NCAM regulatory axis which plays important roles in controlling glioma cell invasion and tumorigenesis.
|
26255203 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Wnt activity, evidenced by nuclear β-catenin in our cohort and high expression of its target AXIN2 (axis inhibitor protein 2) in published glioma datasets, was associated with shorter patient survival, although this was not statistically significant.
|
26222502 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-155 contributes to the progression of glioma by enhancing Wnt/β-catenin pathway.
|
25672607 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-215, an activator of the CTNNBIP1/β-catenin pathway, is a marker of poor prognosis in human glioma.
|
26317904 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistently, MAGI3 overexpression in glioma cells C6 suppressed expression of β-catenin target genes including Cyclin D1 and Axin2, whereas MAGI3 knockdown in glioma cells U373 and LN229 enhanced their expression.
|
26452219 |
2015 |